INDV
What one share of Indivior Pharmaceuticals holds
Pharmaceutical Preparations
Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease.
Indivior Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $10.32 |
|---|---|
| Profit | $2.76 |
| Capex (buildings and equipment) | $0.55 |
| Free cash flow | −$0.86 |
| Cash and investments | $1.88 |
| Debt | $4.13 |
| Book value | −$1.76 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $6.48 | −$0.30 | $0.04 | −$0.06 | — | −$0.11 |
| 2023 | $7.98 | −$0.92 | $0.06 | −$2.25 | — | −$1.35 |
| 2024 | $8.93 | $0.05 | $0.22 | $0.05 | — | −$2.70 |
| 2025 | $9.68 | $1.64 | $0.52 | −$0.73 | — | −$0.78 |